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Abstract Sunitinib, a multi-targeted receptor tyrosine
kinase inhibitor, is a first-line treatment for metastatic renal
cell carcinoma (mRCC) in patients in ‘low’ and ‘interme-
diate’ Memorial Sloan Kettering Cancer Center and Heng
risk groups. Disruptions of hematopoiesis, such as anemia,
neutropenia, and thrombocytopenia, are typically observed
during sunitinib treatment. When it comes to RBC
parameters, an increase in mean cell volume (MCV) tends
to occur, meeting the criteria for macrocytosis in some
patients (MCV[ 100 fL). We examined changes in RBC
parameters of 27 mRCC patients treated with sunitinib
(initial dose of 50 mg/day, 6-week treatment: 4 weeks on,
2 weeks off) and correlated them with progression-free
survival time (PFS). Patients who had macrocytosis after 3
treatment cycles had significantly longer PFS than those
whose MCV stayed less than 100 fL (not reached vs.
11.2 months, p\ 0.001). We also found a correlation
between MCV values after the first and third treatment
cycles and the risk of progression: HR of 0.9 (0.81–0.99)
and 0.76 (0.65–0.90) per 1 fL increase in MCV, respec-
tively. The mechanism of MCV elevation during sunitinib
treatment has not yet been fully explained. One of the
probable causes is sunitinib’s inhibitory influence on c-Kit
kinase, as is the case with imatinib. For mRCC patients,
this phenomenon could help predict PFS, but since our
sample was small, further studies are essential.
Keywords Metastatic renal cell carcinoma (mRCC) 
Predictive factors  Macrocytosis  MCV  Progression-free
survival (PFS)
Introduction
Sunitinib is a TKI that acts on various receptors and
kinases, including the vascular endothelial growth factor
receptors 1–3 (VEGFR1–VEGFR3), the platelet-derived
growth factor receptors (PDGFRa and PDGFRb), the stem
cell factor receptor (Kit), the Fms-like tyrosine kinase 3
(Flt-3), and the colony-stimulating factor-1 receptor (CSF-
1R) [1]. The medical community typically recommends
sunitinib as a first-line treatment in mRCC patients clas-
sified as belonging to ‘low’ and ‘intermediate’ risk group
according to MSKCC and Heng criteria [2].
However, sunitinib is associated with adverse events
that were previously uncommon in systemic treatment.
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These include cutaneous, vascular, and mucosal toxicities,
such as hand–foot syndrome, skin rash, and hypertension,
and endocrine toxicities like hypothyroidism [3, 4].
Moreover, abnormalities in laboratory tests, including
cytopenias (leukopenia, neutropenia, anemia, and throm-
bocytopenia), and disruptions of renal and liver function,
are also observed during sunitinib treatment [3–6].
These adverse effects seem to be related to sunitinib
mechanisms of action, i.e., its inhibition of signaling
pathways.
In a phase III clinical trial, Motzer et al. [4] found that
treating mRCC patients with sunitinib resulted in signifi-
cantly higher response rates (31 vs. 6 %) and PFS (11.0 vs.
5.0 months) than treatment with interferon alpha, but
clinical practice shows significant differences in both
treatment outcomes and sunitinib toxicity across patients.
Studies have shown that sunitinib-induced adverse effects
like hypertension, hypothyroidism, hand–foot syndrome
(HFS), myelosuppression, and hypothyroidism (as well as
their co-occurrence) could signal the drug’s activity in the
body and help predict treatment outcome parameters like
ORR, PFS, and OS [7–10].
A number of studies that evaluated complete blood
count (CBC) during sunitinib treatment found red blood
cell (RBC) disruptions. In addition to lower RBC and HGB
counts, authors have noted increases in MCV, which were
reversible after treatment completion [11]. The mechanism
that causes this phenomenon has not yet been fully
explained.
Our aim in this study was to assess whether erythrocyte
indices, especially macrocytosis, predicted PFS in a
homogenous group of clear cell mRCC patients.
Materials and methods
Patient selection and therapeutic procedure
This was a retrospective study of 27 patients treated at the
Department of Oncology at the University Hospital in
Krakow, Poland, between 2008 and 2013, and selected
according to the following inclusion criteria as follows:
diagnosis of clear cell mRCC, application of sunitinib as a
first-line treatment for the mRCC, prior nephrectomy (total
or nephron-sparing surgery), and good or intermediate
MSKCC risk prognosis. All patients received sunitinib on a
standard schedule (initial dose of 50 mg/day, 6-week
course: 4 weeks on, 2 weeks off). The hematology test
profile included total erythrocyte count (RBC), hemoglobin
(HGB), hematocrit (HCT), and erythrocyte indices: mean
cell volume (MCV), mean cell hemoglobin (MCH), mean
cell hemoglobin concentration (MCHC), and red cell dis-
tribution width—coefficient of variation (RDW-CV). We
received permission to conduct this study from the
Jagiellonian University Bioethics Committee (permission
number KBET/45/B/2013).
Data collection and evaluation criteria
Our data set consisted of patient demographics, laboratory
test results (including CBC, TSH, cobalamine, and folic acid
levels), treatment delays, treatment duration, and treatment
outcomes. The CBC profile was evaluated before starting
sunitinib (baseline values) and at the end of each course of
treatment. TSH was evaluated after every other course of
treatment, while cobalamine and folic acid levels were
assessed whenever the supervising physician prescribed it.
Hematology parameters were measured using the 5 diff
Sysmex XE 2100 Hematological Analyzer (Sysmex Corp.,
Japan). Vitamin B12, folic acid, and TSH levels were mea-
sured with electrochemiluminescentric ECLIA methodol-
ogy on Cobas 6000 (Roche Diagnostic, Mannheim,
Germany). The reference range was 141–489 pmol/L
(191–663 pg/mL) for serum vitamin B12; 10.4–42.4 nmol/
L (4.6–18.7 ng/mL) for folic acid; and 0.27–4.20 lIU/mL
for TSH. Laboratory tests were carried out by the Diagnos-
tics Department of the University Hospital in Krakow.
Statistical analysis
Nominal variables are summarized as the number of
patients (percentage of the group) and continuous variables
as median (lower/upper quartile) or mean ± SD, according
to distribution (tested for normality using Shapiro–Wilk
test). Baseline RBC and erythrocyte indices were compared
with values after 3 and 5 cycles, using repeated-measures
ANOVA with the Bonferroni post hoc test. Differences
between groups with and without hypothyroidism as well
as with or without vitamin B12 deficiency were tested with
a t test. PFS values were calculated with a start date at the
beginning of the sunitinib treatment and end date at pro-
gression or death, or censored at the end of the study, in
case of patients who remained in treatment thereafter. PFS
was estimated using the Kaplan–Meier method and com-
pared with the log-rank test. The associations between
RBC and erythrocyte indices with PFS were studied using
univariate and MSKCC-adjusted Cox proportional hazards
models; resulting hazard ratios (HRs) are reported with
95 % confidence intervals.
Results
Clinical characteristics of the study group (N = 27) at the
start of the sunitinib treatment are shown in Table 1.
During the study period, we observed progression in 20
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patients (74 %), after a minimum of 2 cycles (i.e.,
12 weeks) and a maximum of 21 cycles (i.e., about
29 months). The remaining 7 patients (26 %) continued
treatment at the end of the study. Twenty-four patients
stayed in treatment after 3 cycles, and 20 patients were in
treatment for at least 6 cycles ([8 months). Median PFS
for the whole study group was 12.5 months (lower/upper
quartile 5.2/29.4 months).
We observed significant changes in RBC counts and other
indices, and these were most pronounced during the first 3
treatment cycles (Fig. 1). After the first cycle, we observed
lower RBC counts in 25 patients (93 %); after 3 cycles, all
but one patient had RBC counts lower than baseline. After
the first treatment cycle, MCV and MCH increased in 23
patients (85 %). After 3 cycles, all patients who stayed in
treatment (N = 24) had MCH values higher than baseline,
and the MCV values of all but one patient were also higher
than baseline. We checked the statistical significance of
these changes in the subgroup of 20 patients who were in
treatment for at least 6 cycles (Table 2), and our analysis
confirmed that the significant changes occurred during the
first 3 treatment cycles, followed by a plateau. The simul-
taneous decrease in HGB concentrations andHCTwasmuch
less consistent (Fig. 1); however, average values after 3
treatment cycles were also significantly lower than baseline
(Table 2). RDW-CV showed a fast initial increase, followed
by a decrease and then a plateau (Fig. 1). Only MCHC did
not show significant changes after starting sunitinib
(Table 2, data not shown in Fig. 1).
We monitored TSH concentrations throughout treat-
ment, and therapy-induced hypothyroidism occurred in 12
patients (44 %). However, RBC counts and indices did not
differ significantly between patients who developed
hypothyroidism and those who did not. In particular, MCV
values after 3 treatment cycles were similar for both groups
(96.9 ± 5.3 vs. 98.4 ± 5.6 fL; p = 0.5). The concentra-
tions of vitamin B12 and folic acid were available for only
8 patients (those with highest MCV): none had folic acid
deficiency, but four patients had vitamin B12 levels below
the reference range. Although patients with vitamin B12
deficiency had higher MCV (e.g., after 3 cycles:
104.9 ± 4.9 vs. 100.0 ± 0.6 fL), the differences were not
statistically significant (p = 0.2).
During sunitinib treatment, higher MCV and MCH
values were consistently correlated with longer PFS times
in both univariate and MSKCC-adjusted Cox regressions
(Table 3). The correlations were observed as early as after
the first treatment cycle and became even stronger after 3
cycles, at which point we also observed apparent macro-
cytosis (MCV[ 100 fL) in 6 patients (25 %), who even-
tually had significantly longer PFS times, as shown in
Fig. 2.
Table 1 Baseline
characteristics of patients
Clear cell mRCC patients (N = 27)
Age, years 65 (59/69)
Male sex, N (%) 18 (67)
Fuhrman
Grade 1–2, N (%) 10 (37)
Grade 3–4, N (%) 17 (63)
Nephrectomy (total or nephron sparing), N (%) 27 (100)
Time from diagnosis to systemic treatment\1 year, N (%) 14 (52)
ECOG performance score
0, N (%) 13 (48)
1, N (%) 13 (48)
2, N (%) 1 (4)
MSKCC prognosis
Favorable, N (%) 8 (30)
Intermediate, N (%) 19 (70)
Metastases
No metastases 5 (19)
Lung, N (%) 16 (59)
Liver, N (%) 11 (41)
Bone, N (%) 5 (19)
1 Site, N (%) 15 (56)
2 or more sites, N (%) 7 (26)
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Discussion
Current diagnostic standards during systemic treatment
mandate the inclusion of automated CBC counts. When
it comes to adverse effects of sunitinib therapy on the
hematopoietic system, manual microscope examination
of the peripheral blood smear is also justified. Such
microscopic analysis allows for significantly earlier
diagnosis of macrocytosis. In addition, in automated
MCV analysis, falsely elevated MCV values can be
caused by hyperglycemia, hyperleukocytosis, and cold
agglutinins [12].
Fig. 1 Case profiles showing
changes in RBC counts and
indices for the whole group of
mRCC patients (N = 27) during
sunitinib treatment. Treatment
cycle 0 denotes baseline results.
a RBC change; b HGB change;
c HCT change; d MCV change;
e MCH change; f RDW-CV
change
Table 2 Changes in RBC
counts and indices in patients
who were in treatment for at
least 6 cycles (N = 20)
Baseline After 3 cycles After 5 cycles p
RBC, 9106/ll 4.86 ± 0.52 3.73 ± 0.39 3.74 ± 0.44 \0.001a
HGB, g/dl 13.6 ± 1.1 12.1 ± 1.0 12.3 ± 1.4 \0.001a
HCT, % 41.1 ± 3.3 36.4 ± 3.4 37.0 ± 3.8 \0.001a
MCV, fL 85.5 ± 5.6 98.0 ± 5.3 99.3 ± 5.1 \0.001a
MCH, pg 28.4 ± 2.2 32.7 ± 1.8 32.8 ± 1.9 \0.001a
MCHC, g/dl 33.1 ± 0.7 33.3 ± 1.0 33.1 ± 0.9 0.4
RDW-CV, % 14.5 ± 2.2 15.8 ± 1.1 15.3 ± 0.9 0.022b
a In post hoc comparisons, results after 3 and 5 cycles differ from baseline but not from each other
b Results after 3 cycles differ from baseline while other differences are insignificant
109 Page 4 of 7 Med Oncol (2016) 33:109
123
The macrocytosis is a blood condition in which red
blood cells are larger than normal. Normal MCV value
ranges from 80 to 100 fL [13]. Macrocytosis without
associated anemia can also be a non-pathological phe-
nomenon in newborns and pregnant women. When
macrocytic anemia is diagnosed, it can be either mega-
loblastic or non-megaloblastic. Megaloblastic anemia is
caused by vitamin B12 and folic acid deficiency, which can
lead to ineffective, dysplastic hematopoiesis. Other causes
of macrocytosis, which lead to non-megaloblastic anemia,
include medications (e.g., anticonvulsants, and anti-bacte-
rial and antiretroviral drugs), alcoholism, liver disease,
hypothyroidism, myelodysplastic syndrome, and reticulo-
cytosis (Table 4) [12, 14].
Thus, the proper diagnostic differentiation of macrocy-
tosis requires a detailed patient history, laboratory explo-
ration of parameters that might be causing the
macrocytosis, manual microscope evaluation of the
peripheral blood smear, and automated laboratory blood
tests that take the number of both reticulocytes and
anisocytosis (RDW-CV) into account. Bone marrow anal-
ysis, the most invasive test, may be necessary in mega-
loblastosis, in order to rule out myelodysplastic syndrome.
Treatments relying on tyrosine kinase inhibitors (TKIs),
such as imatinib, sunitinib, and sorafenib, can now be
counted among the possible causes of macrocytosis with
previously unexplained pathomechanisms [11, 15].
In this study, we observed drops in RBC counts and
MCV elevation after the first treatment cycle. The most
significant RBC drop, along with increases in MCV and
MCH values, took place during the first 3 to 4 treatment
cycles, after which RBC, MCV, and MCH values stabi-
lized. This finding diverges from Kloth et al. [16], who
found elevated MCV only after approximately 3 months of
sunitinib therapy. We should add that Kloth et al. analyzed
MCV changes in a non-homogenous group of patients
treated with sunitinib for various diseases and in vari-
ous/successive lines of treatment.
We found that patients who developed macrocytosis
after 3 sunitinib treatment cycles had longer PFS times than
those without macrocytosis. Greatest changes in RBC
parameters occurred after 126 days (3 treatment cycles),
which corresponds to the life span of peripheral erythro-
cytes, which is approximately 120 days. However, increa-
ses in MCV values, noted as early as after the first
treatment cycle, were significantly correlated with longer
PFS.
Kloth et al. [16] explored the relationship between the
development of macrocytosis and various survival param-
eters of patients (n = 533) treated with TKIs (including
sunitinib, sorafenib, pazopanib, imatinib, and vemurafenib)
for a variety of diseases. Only in the case of RCC patients
treated with sunitinib (n = 147) did the authors find a
correlation between the development of macrocytosis and
MCV increases [10 fL, and total survival time
(HR = 0.61, p = 0.031 and HR = 0.58, p = 0.016,
respectively).
The mechanism whereby sunitinib causes MCV eleva-
tion has not yet been definitively established. Potential
causes should include therapy-induced hypothyroidism,
folic acid and cobalamin deficiencies, and sunitinib’s
inhibition of c-Kit kinase [11].
The earliest available information about sunitinib
therapy and MCV elevation was a study published by
Gillesenet et al. [17] in the New England Journal of
Medicine. They described the development of macrocy-
tosis in 6 mRCC patients treated with sunitinib. The initial
treatment dosage was 37.5 mg/day, administered on a
continuous schedule. Macrocytosis was observed after
3–4 months of treatment. Cobalamin deficiency, along
with proper folic acid plasma concentrations, was found
in 5 patients. Five patients had euthyreosis, and one had
subclinical hypothyroidism. No anemia was found.
Patients with cobalamin deficiency received supplemen-
tation intramuscularly. Authors concluded that both
macrocytosis and cobalamin deficiency could be caused
by sunitinib-induced inhibition of cobalamine absorption
in the digestive track. We should note, however, that this
study described only patients who developed macrocyto-
sis, and cobalamin levels were not compared across
Table 3 Significant hazard ratios (95 % confidence intervals) for
progression in MSKCC-adjusted Cox regression
MCV, per 1 fL MCH, per 1 pg
After 1 cycle (N = 27) 0.90 (0.81–0.99) 0.68 (0.53–0.86)
After 3 cycles (N = 24) 0.76 (0.65–0.90) 0.45 (0.28–0.73)
After 5 cycles (N = 20) 0.76 (0.64–0.90) 0.58 (0.38–0.90)
Fig. 2 Kaplan–Meier curves showing progression-free survival in
patients with apparent macrocytosis (MCV[ 100 fL) after 3 cycles
of sunitinib treatment (dashed line) and those with lower MCV values
(solid line). Analysis included patients who were in treatment for at
least 3 cycles (N = 24)
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patients with and without macrocytosis. Billemont et al.
[18] came to a similar conclusion; they observed MCV
elevation in all 40 of their mRCC patients, treated with
sunitinib (initial dosage of 50 mg/day on a 6-week
schedule: 4 weeks on, 2 weeks off). They found lower
levels of cobalamine and folic acid in patients with
macrocytosis (MCV[ 100 fL) than in those without.
They did not find a relationship between these hemato-
logical disturbances and thyroid dysfunction.
Rini et al. [19] carried out a detailed analysis of
hematological parameters in patients treated with suni-
tinib. They found MCV elevation, with accompanying but
nonsignificant lowered HGB concentrations; MCV ele-
vation was greater in patients with biochemical charac-
teristics of hypothyroidism, but the development of
macrocytosis was not limited solely to this group. Patients
who had anemia were not found to have reticulocytosis,
which could explain MCV elevation (since statistically
significant rise in the number of reticulocytes causes the
elevation of overall MCV). In trepanobiopsy, the marrow
of patients treated with sunitinib was hypocellular, with
(reduced) trilineage hematopoiesis, without the domi-
nance of any one lineage. This could indicate the inhibi-
tion of marrow function at the stem cell level, which
could be a consequence of sunitinib’s activity on c-Kit
kinase. This hypothesis is further supported by observa-
tions of gastrointestinal stromal tumor (GIST) patients
treated with imatinib, a c-Kit inhibitor, 42 % of whom
exhibited macrocytosis [20]. On the other hand, mRCC
patients treated with sorafenib, whose activity on c-Kit is
low, were not found to have macrocytosis. In another
study, which evaluated macrocytosis in 29 patients treated
with TKIs for various illnesses, MCV elevation was found
only in mRCC and breast cancer patients receiving suni-
tinib and GIST patients receiving imatinib. Other drugs,
i.e., sorafenib, erlotinib, and B12992, were not found to
affect MCV values [11].
Conclusion
Our results might suggest that the development of macro-
cytosis could be a pharmacodynamic marker of sunitinib’s
activity in the body and a predictive PFS marker. MCV
increases that appear as early as after the first treatment
cycle could also have significant predictive value, enabling
early evaluation of the drug’s activity. Our small sample
size, however, is a major limitation of our study, and our
findings must therefore be tested in larger studies in the
future.
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